The immunomodulatory activity of parasites has been extensively investigated in multiple immune-related diseases. However, dermatological diseases have been off the list for a long time despite their vast incidence and the deleterious consequences of some of them. This study explored the immunomodulatory role of autoclaved Trichinella spiralis (T. spiralis) larvae antigen (ATSLA) as a psoriasis immunotherapeutic candidate in a mice model. Psoriasis was induced in Swiss albino mice using commercial imiquimod cream (IMQ). Mice were randomly divided into the IMQ untreated control group and the IMQ treated group that was treated with ATSLA twice, on day 0 and day 3. Additional mice served as normal controls. Assessment of skin thickness, erythema, and scales was recorded. Total skin scores were calculated. Skin MDA levels, splenic indices, serum and skin IL-23, and tumor necrosis factor alpha (TNF-α) were measured. Skin sections were stained with H&E and immune stained for CD68-positive cells using immunohistochemistry. Treatment with ATSLA significantly reduced skin thickness, erythema, scales, and total skin scores in the IMQ-treated group compared to the untreated control. This was accompanied by a reduction in the splenic index, skin MDA levels, IL-23, and TNF-α in both the skin and serum of the treated group. Pathologically, skin sections of the treated group showed less epidermal thickness, acanthosis, hyperkeratosis, and CD68 cell count. The study concluded the immunotherapeutic activity of ATSLA in experimental psoriatic skin lesions. This will enrich the psoriasis immunotherapeutic list with novel candidates of parasitic origin.
Keywords: Trichinella spiralis antigen; Immunomodulation; Psoriasis immunotherapy; Worm therapy.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.